Abstract: A method for treating choroidal neovascularization in a patient includes administrating as eye drops into the eye of the patient having choroidal neovascularization a therapeutically effective amount of an aqueous ophthalmic composition that is formulated for topical administration as eye drops. The aqueous ophthalmic composition consists essentially of Timolol Maleate at a concentration of about 0.1% to 0.5%, Dorzolamide at a concentration of about 0.5% to 2.5%, Prednisolone at a concentration of about 1.0% to 3.0%, Ketorolac Tromethamine at a concentration of about 0.4% to 1.2%, and sterile water at a concentration of at least about 90.0%.
Abstract: The present invention relates to liquid formulations of Fosaprepitant intended for parenteral administration. Further the invention also describes process for preparing such formulations.
Type:
Application
Filed:
February 26, 2020
Publication date:
June 18, 2020
Applicant:
Leiutis Pharmaceuticals PVT. LTD.
Inventors:
Kocherlakota CHANDRASHEKHAR, Banda NAGARAJU
Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.
Type:
Application
Filed:
November 15, 2019
Publication date:
June 18, 2020
Inventors:
Peter G. Schultz, Arnab K. Chatterjee, Shoutian Zhu, Joshua Payette, Hongchul Yoon, Baiyuan Yang
Abstract: Provided herein are methods of treating cancer in an individual in need thereof, the methods comprising administering to the individual a CXCR7 inhibitor. In some embodiments, additional therapeutic agents are used. Also provided herein are methods of preventing precancerous cells expressing FRS2? from developing into cancer, the method comprising administering to an individual having precancerous cells expressing FRS2? a CXCR7 inhibitor. In some embodiments, additional therapeutic agents are used.
Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
Abstract: The present invention relates to new compounds and compositions comprising active ingredient derivatives of testosterone, and novel testosterone derivatives, novel testosterone methods, novel testosterone compositions, novel testosterone articles of manufacture of pharmaceutical preparations and novel testosterone therapeutic uses thereof.
Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.
Type:
Application
Filed:
November 7, 2019
Publication date:
June 18, 2020
Inventors:
Robert Emil Hodge, Jeffrey Douglas Webster
Abstract: Assay methods for determining purity of a sample of a sterol are provided. These methods include providing an HPLC eluent including a sterol, other compounds related to the sterol and a mobile volatile phase; generating an aerosol of liquid droplets from the HPLC eluent; drying the liquid droplets to obtain residue particles of the sterol; contacting the residue particles of the sterol with an ion stream which applies a size-dependent electrical charge to each of the residue particles to generate an electrical signal and measuring the electrical signal to determine the purity of the sterol in the sample. The sterol can be OXY133 or OXY133 monohydrate.
Type:
Application
Filed:
February 24, 2020
Publication date:
June 18, 2020
Inventors:
Roger E. Harrington, Jerbrena C. Jacobs
Abstract: Improved, stable aspirin formulations for intravenous use are disclosed. Methods of lyophilizing the aspirin from bulk solutions as well as kits containing the lyophilized aspirin and methods of treatment using the same are also disclosed.
Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
Type:
Application
Filed:
February 27, 2020
Publication date:
June 18, 2020
Inventors:
Steven John TAYLOR, Mi-Jeong KIM, Kathleen NUDEL, Timothy F. BRIGGS, Koji YASUDA, Leonard BUCKBINDER, Bernard LANTER, Spencer Cory PECK, Cheri SNEDEKER, Angela SHE, Jessica ALEXANDER, Anna LIANG, Jenny LIU, Dinara GUNASEKERA, David Arthur BERRY, John Patrick CASEY, JR.
Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
Type:
Application
Filed:
September 20, 2019
Publication date:
June 18, 2020
Inventors:
Ben Chal, Erik Mogalian, Reza Oliyai, Rowchanak Pakdaman, Dimitrios Stefanidis, Vahid Zia
Abstract: The disclosure relates to compositions and methods for treating infection, allergic reactions, colitis, IBD, contact dermatitis, psoriasis, atopic dermatitis, graft vs. host disease and disorders and other disease and disorders comprising dendritic cell activation as well as compositions and method to improve allergen sensitization.
Abstract: The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of over-weight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to vitamin B12 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the off-spring, wherein the vitamin B12 is administered to an overweight and/or obese women desiring to get pregnant and/or to the over -weight and/or obese mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.
Type:
Application
Filed:
November 12, 2019
Publication date:
June 18, 2020
Inventors:
Cyrus Cooper, Peter David Gluckman, Irma Silva Zolezzi, Keith Malcolm Godfrey, Catherine Mace
Abstract: This current invention provides methods and agents for preventing and treating autoimmune and lymphoproliferative disease by targeting pathogenic age-associated B cells as well as methods of detecting these pathogenic age-associated B cells as a method of diagnosing and predicting autoimmune disease and other lymphoproliferative and chronic inflammatory disorders. The current invention also provides targets for drug development and basic research for autoimmune diseases and other lymphoproliferative and chronic inflammatory disorders.
Abstract: The purpose of the present invention is to provide a therapeutic agent which is for inflammatory bowel disease and exhibits superior prophylactic or therapeutic effects on inflammatory bowel disease by using miR-29a and/or miR-29h. The prophylactic or therapeutic agent for inflammatory bowel disease comprises composite particles in which miR-29a and/or miR-29b is/are carried on carbonate apatite particles, and said agent is administered systemically.
Abstract: A method of treating a disease associated with fibrosis is disclosed. The method comprises administering to the subject a therapeutically effective amount of exosomes isolated from a hepatic cell-conditioned medium. Administration of agents isolated from the exosomes for treatment of fibrotic diseases is also contemplated.
Type:
Application
Filed:
August 30, 2018
Publication date:
June 18, 2020
Applicant:
Tel HaShomer Medical Research Infrastructure and Services Ltd.
Inventors:
Ziv BEN-ARI, Michal SAFRAN, Maya SULTAN
Abstract: This invention relates generally to compositions and methods for combating inflammatory disease and particularly to the use of food and/or feed compositions for preventing, reducing and/or treating inflammatory disorders, diseases, or discomforts, wherein the compositions comprising at least one specific pectin.
Type:
Application
Filed:
November 26, 2019
Publication date:
June 18, 2020
Inventors:
Hendrik ARIE SCHOLS, Paulus DE VOS, Marco Alexander VAN DEN BERG, Geert BRUGGEMAN, Erik Martinus Andrianus Maria BRUININX, Neha Mohan SAHASRABUDHE, Jan SCHOLTE, Lingmin TIAN, Anton Johannes SCHEURINK
Abstract: A method for wound management in the prevention of bioburden and/or biofilm includes conducting an initial risk assessment protocol with regard to a wound, washing the wound and surrounding skin, applying a polyethylene carbonate composition on and around the wound, eradicating any organisms as methylene chloride of the polyethylene carbonate composition evaporates and polyethylene carbonate polymer of the polyethylene carbonate composition polymerizes, and allowing time for formation of a clear elastomeric film barrier over the wound and around the wound.
Type:
Application
Filed:
December 13, 2019
Publication date:
June 18, 2020
Inventors:
Julie Marie Morris, Jeffrey Steven Elbl
Abstract: Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of A? and ?-syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.
Abstract: The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions.
Type:
Application
Filed:
August 8, 2019
Publication date:
June 18, 2020
Applicant:
Clene Nanomedicine, Inc.
Inventors:
Mark Gordon Mortenson, D. Kyle Pierce, David A. Bryce, Reed N. Wilcox, Anthony Lockett, Mikhail Merzliakov
Abstract: Disclosed herein are compound embodiments that are useful for treating a variety of diseases, particularly neurological diseases, motor neuron diseases, copper deficiency-related diseases, and/or mitochondrial deficiencies. The compound embodiments described herein also can be used in PET methods. Also disclosed herein are embodiments of methods of making and using the compound embodiments, as well as pharmaceutical formulations comprising the disclosed compound embodiments.
Type:
Application
Filed:
February 26, 2020
Publication date:
June 18, 2020
Applicant:
Oregon State University
Inventors:
Joseph Beckman, James Hurst, John Sirois, Chris Beaudry
Abstract: The present invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle wasting occurs. The invention provides the use of inhibitors of glutamine dehydrogenase for the regeneration of skeletal muscle.
Abstract: Contemplated treatment compositions and methods are directed to co-administration of sensitized genetically modified NK cells and recombinant IL-12, wherein the genetically modified NK cells were preferably sensitized by constitutive exposure to IL-2 and wherein the IL-12 is expressed from a recombinant virus or given as an IL-12-antibody conjugate. Such treatment increases IFN? secretion by the sensitized NK cells, and advantageously also increases expression of NKG2D.
Abstract: The present invention provides a cell which comprises; (i) a chimeric antigen receptor (CAR) which comprises an antigen binding domain and an intracellular signalling domain; (ii) a membrane tethering component (MTC) which comprises a first dimerization domain; and (Hi) a signal-dampening component (SDC) comprising a signal-dampening domain (SDD) and a second dimerization domain which specifically binds the first dimerisation domain of the membrane-tethering component. Dimerisation between the MTC and SDC may be controllable with an agent, meaning that the agent can be used to control CAR-mediated cell signalling.
Type:
Application
Filed:
May 14, 2018
Publication date:
June 18, 2020
Inventors:
Shaun Cordoba, Evangelia Kokalaki, Martin Pulé, Simon Thomas, Shimobi Onuoha
Abstract: The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.
Type:
Application
Filed:
November 8, 2019
Publication date:
June 18, 2020
Inventors:
Mathias OELKE, Kristi JONES, Sojung KIM, Lauren SUAREZ, Ken CARTER, Scott CARMER, Dan BEDNARIK, Vineetha EDAVANA, Emily LU
Abstract: The present invention provides compositions and methods for combination therapy comprising administering to a patient in need thereof, drug-resistant immunotherapy, immune checkpoint inhibitors, and chemotherapy for the treatment of cancer.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising cancer antigen-specific cytotoxic T cells; the pharmaceutical composition comprises about 7×106 cells/mL or more, and of the about 7×106 cells/mL, about 90% or more are CD8+ T cells.
Type:
Application
Filed:
December 16, 2019
Publication date:
June 18, 2020
Inventors:
Byoung S. Kwon, Young Ho Kim, Mun Ki Kim, Kwang Hee Kim, You Hyun Kang
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
December 17, 2019
Publication date:
June 18, 2020
Inventors:
Gisela SCHIMMACK, Annika SONNTAG, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Michael ROEMER, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Harpreet SINGH
Abstract: Methods of treating progressive forms of multiple sclerosis are provided, comprising administering adipose-derived stem cells into the central nervous system (CNS). Further provided are improved methods for obtaining ADSCs, which are more cost effective and which provide higher yields compared to currently used methods.
Abstract: Methods of treating an aging-associated disease, as well as inhibiting aging in a subject, by administering pharmaceutical compositions comprising unmodified and modified MSCs and their exosomes are provided.
Abstract: Provided herein are, inter alia, methods and compositions for reducing and/or preventing ocular endothelial cell loss, and for treatment and/or prevention of ocular diseases.
Type:
Application
Filed:
April 27, 2018
Publication date:
June 18, 2020
Inventors:
Reza Dana, Ahmad Kheirkhah, Ula V. Jurkunas
Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes or a sterile fecal filtrate for treating Parkinson's disease and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.
Abstract: A method for obtaining epithelial organoids is provided. In one embodiment, the method comprises culturing one or more epithelial ducts, epithelial duct fragments and/or epithelial stem cells isolated therefrom in contact with an extracellular matrix in the presence of a basal medium, wherein the medium is free of FGF and/or nicotinamide. Organoids obtained by the methods described herein, and uses thereof, are also provided.
Type:
Application
Filed:
May 29, 2018
Publication date:
June 18, 2020
Inventors:
Charis-Patricia Segeritz, Ryan Conder, Michael Riedel
Abstract: The present invention pertains to hepatocytes, liver progenitor cells, cholangiocytes, liver sinusoidal endothelial progenitor cells, liver sinusoidal endothelial cells, hepatic stellate progenitor cells, hepatic stellate cells, and liver cellular tissue models, as well as to methods for preparing these cells. The present invention also pertains to a cell fraction comprising liver progenitor cells, liver sinusoidal endothelial progenitor cells, or hepatic stellate progenitor cells. The present invention also pertains to a pharmaceutical composition or kit comprising the above-mentioned cells, a liver cellular tissue model, or a cell fraction.
Type:
Application
Filed:
November 15, 2019
Publication date:
June 18, 2020
Applicant:
The University of Tokyo
Inventors:
Atsushi Miyajima, Taketomo Kido, Yuta Koui, Ayaka Kobayashi
Abstract: A method includes covering or contacting a portion of a parathyroid of a subject with a shield including extraembryonic tissue and/or a parathyroid protective injection. The covering occurs during a neck or reconstructive surgery of the subject.
Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
Abstract: A cosmetic or dermatological preparation that contains an aqueous and a lipophilic fish egg extract for replumping skin; for increasing the incorporation of triglycerides in adipocytes; for increasing the expression of laminin, preferably of laminin-5 and most preferably of laminin-5 ? sub-unit; and/or for maintaining the skin elasticity and/or resilience of human skin.
Abstract: The present invention relates to a coral composite extract, a composition including the same and a method of producing the same. The coral composite extract includes at least two briarane-type diterpenoid compounds from corals of Briareum violaceum, B. excavatum and B. stechei, thereby being applied as an effective ingredient of a skin external use composition, a cosmetic composition and a medicinal composition.
Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating chronic fatigue syndrome and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.
Abstract: The invention relates to a fecal microbiota sample for use in the prevention and/or treatment of infectious or non-infectious complications resulting from allogeneic hematopoietic stem cell (HSC) transplantation, or for the treatment of cancer in a recipient patient, said fecal microbiota sample and said hematopoietic stem cells originating from the same donor subject, or said fecal microbiota sample being administered prior to HSC transplantation.
Abstract: Provided herein are compositions comprising Oxalobacter formigenes (Of)-derived factors and variants and fragments thereof, and method of use thereof for the treatment/prevention excess oxalate levels and conditions and diseases related thereto.
Abstract: Compositions and methods for treating or reducing the severity of occurrence of a parasitic worm or helminth infection in a subject are described. The methods include administering to the subject a therapeutically effective amount of a composition comprising isolated native, bioactive nematicidal crystals formed from a single type of nematicidal crystal protein. The isolated native, bioactive nematicidal crystals are substantially free of any bacterial spores or host bacterial proteins, other than nematicidal crystal protein in the form of a crystal. Methods for making isolated native, bioactive nematicidal crystals are also described. The crystal proteins may be full length, truncated, variant, or sub-variant Cry proteins. Examples of crystal proteins include Cry5B, Cry21, Cry14A, Cry6A, and Cry13A.
Abstract: The invention provides a method which comprises administering an effective amount of a probiotic composition including Lactobacillus plantarum TWK10 for improving inflammation after exercise. The Lactobacillus plantarum TWK10 is deposited in Taiwan Food Industry Research and Development Institute (FIRDI) with the accession number BCRC910734, and in China General Microbiological Culture Collection Center (CGMCC) with the accession number CGMCC 13008.